BlackThorn Therapeutics, Inc.
http://www.blackthornrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BlackThorn Therapeutics, Inc.
Neumora Launches With $500m To Advance Personalized Neuroscience Drugs
Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.
Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders
BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- Neumora Therapeutics, Inc.